RELATIONSHIP BETWEEN PREDNISOLONE THERAPY AND OCCURRENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS TYPE B

为了解糖皮质激素(强的松龙，PSL)治疗HBeAg阳性慢性肝炎后，HBVDNA与肝细胞DNA的整合情况及HBVDNA的复制情况，我们观察了PSL治疗后HBeAg阳性慢性肝炎患者血清和肝脏中HBVDNA的变化。PSL用药3周后，肝组织中HBVDNA的增加达到最大值，升高率为治疗前的3.2倍。PSL增加了肝脏中的游离HBVDNA，并未新检测到HBVDNA与肝细胞DNA的整合。PSL暂时促进了HBVDNA的复制，但不增加HBVDNA与肝细胞DNA的整合，因此发生癌症的风险可能很小或为零。

IN ORDER TO CLARIGY THE INTEGRATION OF HEPATITIS B VIRUS (HBV-DNA) INTO THE LIVER CELL DNA AND REPLICATION OF HBV FOLLOWING ADMINISTRATION OF GLUCOCORTICOID(PREDNISOLONE, PSL), WE INVESTIGATED THE CHANGE OF HBV-DNA IN SERA AND LIVERS IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS TREATED WITH PSL.HBV-DNA IN SERA INCREASED FOLLOWING PSL ADMINISTRATION. THREE WEEKS AFTER PSL USE THE INCREASE OF HBV-DNA BECAME MAXIMUM AND THE INCREASED RATIO WAS 3.2 TIMES BEFORE THE TREATMENT.ALTHOUGH FREE HBV-DNA IN LIVERS INCREASED BY PSL, THE INTEGRATION OF HBV-DNA INTO LIVER CELL DNA WAS NOT NEWLY DETECTED.PSL PROGRESS THE REPLICATION OF HBV TEMPORALLY, BUT IT WAS NOT INCREASE THE INTEGRATION OF HBV-DNA INTO LIVER CELL DNA, SO THE RISK OF CANCER OCCURENCE MAY BE LITTLE OR NONE.